Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Tharimmune, Inc. - Common Stock (NQ:THAR)

2.950 -0.020 (-0.67%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Tharimmune, Inc. - Common Stock

< Previous 1 2 Next >
Tharimmune Reports Pharmacokinetic Simulation Results for TH104 as Prophylaxis Against Respiratory Depression from Fentanyl and Ultrapotent Opioids, Highlighting Potential Superiority Over Existing Treatments
Via ACCESS Newswire
Tharimmune Secures Key Global Patents for TH-104, Laying Foundation for Broader Indications Following Initial Development as a National Security Medical Countermeasure Against Weaponized Fentanyl
Via ACCESS Newswire
Nancy Davis, Visionary Philanthropist and Founder of Race to Erase MS and Cure Addiction Now Appointed to the Tharimmune Board of Directors
Via ACCESS Newswire
Tharimmune Issues Comprehensive Corporate Update including Lead TH104 as Critical National Security Solution Against Weaponized Fentanyl and TH023 Poised to Revolutionize Oral Antibody Delivery
Via ACCESS Newswire
Tharimmune Announces Pricing of $1.74 Million Registered Direct Public Offering of Common Stock and Warrants
Via ACCESS Newswire
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
Via ACCESS Newswire
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
Via ACCESS Newswire
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
Via ACCESS Newswire
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
Via ACCESS Newswire
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
Via ACCESS Newswire
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
Via ACCESS Newswire
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Via ACCESS Newswire
Tharimmune Announces Positive FDA Feedback on NDA Path for TH104 for Prophylaxis of Respiratory and/or CNS Depression for Ultrapotent Opioid Exposure
Via ACCESS Newswire
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Via ACCESS Newswire
Tharimmune Announces Positive Target Engagement with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick Technology
Via ACCESS Newswire
Tharimmune to Present at the Microcap Conference 2025
Via ACCESS Newswire
Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Via ACCESSWIRE
Tharimmune Announces $2.02 Million Private Placement to Advance Development Programs
Via ACCESSWIRE
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Via ACCESSWIRE
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease
Via ACCESSWIRE
Tharimmune Granted European Patent for Delivery of Optimized Molecularly Targeted Therapeutics
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis
Via ACCESSWIRE
Tharimmune Announces Upcoming Conference Presentations
Via ACCESSWIRE
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company
Via ACCESSWIRE
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab
Via ACCESSWIRE
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory Board
Via ACCESSWIRE
Tharimmune Appoints Global Business Executive David H. Clarke as Key Strategic Advisor
Via ACCESSWIRE
Tharimmune Launches New Website as Discussions with FDA Continue for Phase 2 Clinical Trial with TH104
Via ACCESSWIRE
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.